A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-70 lat
- •Rak piersi zaawansowany lub przerzutowy z niskim HER2
- •Wcześniejsze leczenie chemioterapią (1-2 schemat)
- •Spodziewany czas przeżycia co najmniej 12 tygodni
- •Ogólny stan zdrowia pozwalający na leczenie (klasa ECOG 0-1)
- •Prawidłowe funkcjonowanie szpiku kostnego, wątroby i nerek
- •Gotowość do stosowania antykoncepcji przez czas leczenia i 6 miesięcy po
- •Zrozumienie wymogów badania i chęć uczestnictwa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Oncology Hospital, Chinese Academy of Medical Sciences
Beijing, China
Trial contact
Binghe Xu, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.